FR3062570B1 - ANTI-ANGIOGENESIS PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC PENTADEPSIPEPTIDE AS EFFECTIVE COMPONENT - Google Patents
ANTI-ANGIOGENESIS PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC PENTADEPSIPEPTIDE AS EFFECTIVE COMPONENT Download PDFInfo
- Publication number
- FR3062570B1 FR3062570B1 FR1851006A FR1851006A FR3062570B1 FR 3062570 B1 FR3062570 B1 FR 3062570B1 FR 1851006 A FR1851006 A FR 1851006A FR 1851006 A FR1851006 A FR 1851006A FR 3062570 B1 FR3062570 B1 FR 3062570B1
- Authority
- FR
- France
- Prior art keywords
- angiogenesis
- effective component
- nmssv
- present
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003527 anti-angiogenesis Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 abstract 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne une composition pour l'inhibition de l'angiogenèse, contenant du néo-N-méthylsansalvamide (NMSSV), qui est un pentadepsipeptide cyclique, en tant que composant efficace, et spécifiquement, puisque le NMSSV de la présente invention présente une activité excellente qui inhibe la migration cellulaire et la formation des tubes associées à l'angiogenèse, et inhibe d'une façon dépendante de la concentration l'angiogenèse induite par un facteur de croissance de l'endothélium vasculaire, on s'attend à ce que le NMSSV de la présente invention puisse inhiber l'angiogenèse et être utilisé de façon utile en tant qu'agent thérapeutique pour diverses maladies dans lesquelles l'angiogenèse est régulée anormalement.The present invention relates to a composition for inhibiting angiogenesis, containing neo-N-methylsansalvamide (NMSSV), which is a cyclic pentadepsipeptide, as an effective component, and specifically, since the NMSSV of the present invention exhibits a excellent activity which inhibits cell migration and tube formation associated with angiogenesis, and in a concentration dependent manner inhibits angiogenesis induced by vascular endothelial growth factor, it is expected that the NMSSV of the present invention can inhibit angiogenesis and usefully be used as a therapeutic agent for various diseases in which angiogenesis is abnormally regulated.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170018103 | 2017-02-09 | ||
| KR20170018103 | 2017-02-09 | ||
| KR1020180011886 | 2018-01-31 | ||
| KR1020180011886A KR102022631B1 (en) | 2017-02-09 | 2018-01-31 | Pharmaceutical composition for the Anti―Angiogenesis containing cyclic pentadepsipeptide as an effective ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3062570A1 FR3062570A1 (en) | 2018-08-10 |
| FR3062570B1 true FR3062570B1 (en) | 2021-03-12 |
Family
ID=62948404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1851006A Active FR3062570B1 (en) | 2017-02-09 | 2018-02-07 | ANTI-ANGIOGENESIS PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC PENTADEPSIPEPTIDE AS EFFECTIVE COMPONENT |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR3062570B1 (en) |
| WO (1) | WO2018147615A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102170939A (en) * | 2008-05-22 | 2011-08-31 | 卡鲁斯治疗有限公司 | Depsipeptides and their therapeutic use |
| KR101119561B1 (en) * | 2009-01-02 | 2012-03-07 | 중앙대학교 산학협력단 | Microorganism of Fusarium genus producing cyclic pentadepsipeptides |
| KR101120565B1 (en) * | 2009-01-02 | 2012-03-09 | 중앙대학교 산학협력단 | Novel cyclic pentadepsipeptide(I) and its use |
| WO2011081229A1 (en) * | 2009-12-29 | 2011-07-07 | 이화여자대학교 산학협력단 | Pharmaceutical composition for inhibiting angiogenesis |
-
2018
- 2018-02-06 WO PCT/KR2018/001560 patent/WO2018147615A1/en not_active Ceased
- 2018-02-07 FR FR1851006A patent/FR3062570B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018147615A1 (en) | 2018-08-16 |
| FR3062570A1 (en) | 2018-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46269B1 (en) | METHODS OF TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTRATION OF AN IL-4R INHIBITOR | |
| MA47399B1 (en) | Derivatives of 7-phenylethylamino-4h-pyrimido [4,5-d] [1,3] oxazin-2-one as inhibitors of the mutated form of idh1 and idh2 proteins | |
| CU20190015A7 (en) | HIGHLY CONCENTRATED, LOW VISCOSITY, INHIBITING ANTIBODY FORMULATIONS OF MASP-2 AND COMPOSITION OF PHARMACEUTICAL COMPOSITIONS | |
| MA52219B1 (en) | TREATMENT OF HIDRADENITIS SUPPURATIVE WITH JAK INHIBITORS | |
| MA40434B1 (en) | 1 - ((3s, 4r) -4- (3-fluorophenyl) -1- (2-methoxyethyl) pyrrolidin-3-yl) -3- (4-methyl-3- (2-methylpyrimidin-5-yl) - 1-phenyl-1h-pyrazol-5-yl) urea as inhibitor of trka kinase | |
| EA202090932A1 (en) | METHODS OF ADMINISTRATION OF SOME VMAT2 INHIBITORS | |
| MA39219A1 (en) | New lrrk2 Kinase Inhibitor Compounds Used to Treat Parkinson's, Alzheimer's and Amyotrophic Lateral Sclerosis | |
| EA201800499A1 (en) | THYROZINKINASE INHIBITOR FOR THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS, COMPOSITION, MEDICINE, SET | |
| FR3126511B1 (en) | “Metastable β titanium alloy watch spring, and its manufacturing process” | |
| MA44206A (en) | ORODISPERSIBLE TABLET CONTAINING ESTETROL | |
| EP3345613A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING, AS AN ACTIVE INGREDIENT, A FUSION PROTEIN IN WHICH A PEPTIDE PENETRATING TUMORS AND AN ANTIANGIOGENESIS AGENT ARE MERGED FOR THE PREVENTION AND TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASES | |
| MX2021002935A (en) | Csf-1r antibody formulation. | |
| MA42701B1 (en) | Rapid acting insulin compositions | |
| PE20200740A1 (en) | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS OF BRUTON TYROSINE KINASE | |
| EA202190960A1 (en) | CONDENSED PYRROLINES THAT ACT AS INHIBITORS OF UBIKVITIN SPECIFIC PROTEASE 30 (USP30) | |
| CL2021000683A1 (en) | N-substituted dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
| MA46548B1 (en) | Fsh for the treatment of infertility | |
| MA61732A1 (en) | VOLTAGE-SENSITIVE POTASSIUM CHANNEL OPENER FOR USE IN THE TREATMENT OF ANHEDONIA | |
| FR3063645B1 (en) | ACEFAPC FOR THE TREATMENT OF ACETYLCHOLINE DEPENDENT DISEASES | |
| MA37317B1 (en) | Antibody formulation il-17 | |
| MA46611A (en) | COMBINATION TREATMENTS INCLUDING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND / OR COGNITIVE DISORDERS | |
| FR3062570B1 (en) | ANTI-ANGIOGENESIS PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC PENTADEPSIPEPTIDE AS EFFECTIVE COMPONENT | |
| FR3100128B1 (en) | Pharmaceutical composition for inhibiting HIV infectivity, treating acquired immunodeficiency syndrome (AIDS) and its complications | |
| MA45639B1 (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
| WO2018199854A3 (en) | Left atrial appendage sizing and elimination devices and related methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20200619 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |
|
| PLFP | Fee payment |
Year of fee payment: 5 |
|
| PLFP | Fee payment |
Year of fee payment: 6 |
|
| PLFP | Fee payment |
Year of fee payment: 7 |
|
| PLFP | Fee payment |
Year of fee payment: 8 |